A first-in-human trial of intravesical BH011, a novel docetaxel formulation, in patients with high risk non-muscle invasive bladder cancer (HR-NMIBC) after BCG failure: Results from a phase 1 study.

Authors: Xiaolin Lu, Dingwei Ye, Hailong Hu, Mingde Lei, Zihan Xue, Ning Kang, Qun Sun, Xiaohua Wei

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e16605

Source: Full article

e16605